Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Tom Lee Says Crypto’s Rally Is Signal: Fed Will Ease And Democrats Will Back CLARITY Act After Midterms

Tom Lee Says Crypto’s Rally Is Signal: Fed Will Ease And Democrats Will Back CLARITY Act After Midterms

CoinpediaCoinpedia2026/10/06 01:39

Fundstrat’s Tom Lee says crypto is telling investors something the wider market has missed. Speaking on CNBC, he argued that digital assets and tech stocks could not be rising if tighter money was really on the way, and predicted that Democrats will swing behind the CLARITY Act once the midterms are over.

Why crypto’s strength matters

Lee said markets had been bracing for a “maximum hawkish” Federal Reserve. Traders had priced in three rate hikes, including a 75% chance of one in October.

Last week’s softer jobs report changed that picture, in his view. He pointed to tech stocks at new highs and crypto “doing so well” as evidence. These assets “can’t do well in the face of tightening monetary conditions,” Lee said, so they are anticipating easier financial conditions ahead.

His contrarian call on the CLARITY Act

Lee said AI stocks and crypto stalled ahead of the midterms because investors assumed Democrats oppose both data centres and the CLARITY Act. He takes the opposite view and expects Democrats to start supporting both after the vote.

The crypto market structure bill failed a Senate procedural vote 49 to 50 on September 15, well short of the 60 votes it needed. Lee’s forecast suggests that setback may not be final.

Midterms as a turning point

With the midterms about four weeks away, Lee called the vote a “clearing event” and a likely risk-on signal “regardless of outcome.” A Congress controlled by Democrats would mean gridlock, he said, and markets like gridlock.

Inflation, yields and the Fed

Lee expects softer inflation readings over the next six months as one-off pressures fade, with the next report due in two weeks. That would let the Fed step back from its hawkish stance and allow bond yields to settle.

He said the 10-year Treasury yield stood at 4.75% before the Jackson Hole meeting. Anything under 5% would be read as positive for risk assets, he said, and he sees a good chance of that within six months.

S&P 500 target: up to 8,400

The S&P 500 closed back above 7,700 on Friday. Lee sees as much as 9% further upside this year, which points to 8,200 to 8,400. His reasons:

  • Earnings are accelerating: Third-quarter profit growth is likely to come in near 30%.
  • Stocks have become cheaper: Estimates for 2027 earnings have risen more than 20% this year, while the index has gained less than that.
  • Oil is helping: High oil prices strengthen the US economy because the country is an exporter.

The risk he still sees

Lee has not ruled out a pullback. He said a “speed bump” could come between mid-October and the midterms. But with sentiment already negative and investors cautious, he is reluctant to call it with confidence.

News Image 0
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Monnalisa shares delist from Euronext Growth Milan

Monnalisa’s delisting from trading on Euronext Growth Milan took effect today. The company is preparing a shareholder buyback process led by Modamet and Jafin Due for investors seeking to sell. Further details are due in coming days on the purchase window and a single settlement date for the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monnalisa S.p.A. published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.

Bitget•2026/10/06 16:04

Updated: 3-ArriVent’s cancer drug failed to “significantly” delay disease progression, stock price plummeted

Updated stock data and added analyst comments in paragraphs 8 and 10 Christy Santhosh - Reuters, October 6 - ArriVent BioPharma (AVBP.O) announced on Tuesday that its oral therapy for a rare form of lung cancer failed to significantly delay disease progression in a late-stage clinical trial, causing the company's share price to plunge by nearly 60% in early trading. The therapy, firmonertinib, was tested in treatment-naïve advanced non-small cell lung cancer (NSCLC) patients carrying a gene mutation known as EGFR exon 20 insertion, which may promote cancer growth. This mutation accounts for about 0.5% to 1% of all NSCLC cases. NSCLC makes up around 85% of all lung cancer cases. An assessment by independent reviewers showed that ArriVent’s 240 mg dose therapy extended median progression-free survival to 11 months in the trial, compared to just 9.5 months for the chemotherapy group. CEO Bing Yao stated that the improvement in progression-free survival (i.e., the period during which a patient's cancer does not worsen or spread) was not "significant". "These disappointing results are not what we had hoped for, especially for patients who... are in urgent need of more effective treatment options." The company said it is reviewing the complete dataset to determine the most appropriate development path for firmonertinib, and no new safety signals were observed in the trial. BTIG analyst Jeet Mukherjee noted that the main reason the trial appears to have failed was the control group's performance exceeding expectations—their progression-free survival reached 9.5 months, when only 7.5 to 8 months was anticipated; firmonertinib’s 11-month result matched the expected range of 9 to 11 months. Additionally, firmonertinib is currently undergoing an advanced clinical trial in NSCLC patients with rare EGFR PACC mutations in their tumors. "This result is a significant setback for the exon 20 mutation treatment space, but the PACC program still has clinical support," said Clear Street analyst Kaveri Pohlman. The therapy has been approved in China for NSCLC patients carrying specific mutations. (To aid non-English speakers, Reuters has automated the translation of its reports into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of these translated texts and they are provided for reader convenience only. Reuters is not responsible for any damages or losses arising from the use of automated translation features.)

路透社•2026/10/06 15:18
Updated: 3-ArriVent’s cancer drug failed to “significantly” delay disease progression, stock price plummeted